A Physician Who Actually Uses Peptides in Practice
Dr. Ashley Froese has become one of the more credible voices in the peptide space, and this video shows why. She is a practicing physician who prescribes peptides to real patients, tracks their outcomes, and is willing to talk openly about both what works and what does not. That combination is surprisingly rare. Most peptide content comes from either researchers who have never treated a patient or influencers who have never read a study. Dr. Froese sits in the middle, and that perspective is valuable.
The title of this video sounds hyperbolic. Changing medicine forever? But once you watch it, you realize she is making a more measured argument than the clickbait suggests. Her point is that peptide therapeutics represent a category of medicine that does not fit neatly into existing regulatory and clinical frameworks, and that gap is creating both opportunity and risk.
Why Peptides Are Different From Traditional Drugs
Dr. Froese spends time on something that most peptide videos skip entirely: the pharmacological reasons peptides behave differently from small-molecule drugs. Traditional pharmaceuticals, things like statins, SSRIs, and blood pressure medications, are small molecules that typically work by blocking a single receptor or enzyme. They are blunt instruments by design. Block the enzyme, get the effect.
Peptides work through a different logic. They are short chains of amino acids, usually between 2 and 50 amino acids long, that mimic or modulate natural signaling molecules in the body. Because your body already uses peptide signals to regulate everything from inflammation to tissue repair to hormone release, exogenous peptides can slot into existing biological pathways with a specificity that small molecules cannot match.
The practical implication is that peptides tend to have fewer off-target effects than traditional drugs. A peptide that mimics a natural repair signal activates the same downstream pathways that your body uses during normal healing. A small-molecule drug that blocks an enzyme to achieve a similar effect often disrupts other pathways that use the same enzyme for different purposes. This is why statin users get muscle pain, SSRI users get sexual side effects, and anti-inflammatory drugs cause stomach ulcers. The drugs work, but they work imprecisely.
Dr. Froese is careful to note that this is a general principle, not a guarantee. Not all peptides are safe just because they are peptides. But the class as a whole offers a therapeutic precision that traditional pharmaceuticals often lack.
The Regulatory Vacuum
This is where the video gets really interesting. Dr. Froese walks through the current regulatory situation with peptides in the United States, and it is genuinely complicated. Most peptides exist in a gray zone. They are not FDA-approved drugs for the conditions people use them for. They are not dietary supplements. They are not controlled substances (with some exceptions). They occupy a regulatory no-man's land that creates problems for both doctors and patients.
The FDA has been cracking down on certain peptides, moving some from research chemical status to Category 2 designation, which effectively restricts compounding pharmacies from producing them. BPC-157 is the highest-profile example. The FDA has not said BPC-157 is dangerous. They have said it does not meet the criteria for compounding under current rules. The distinction matters, but in practice, the result is the same: patients who were getting BPC-157 from compounding pharmacies under physician supervision are now pushed toward unregulated online sellers with no quality control.
Dr. Froese argues that this is backwards. The solution to limited safety data on peptides is not to push them underground where there is zero quality control and zero physician oversight. It is to create a regulatory pathway that allows clinical use while requiring proper monitoring and outcome reporting. She is not the only physician making this argument, and it is hard to disagree with the logic.
Which Peptides She Actually Prescribes
Rather than listing every peptide that exists, Dr. Froese focuses on the ones she uses most frequently in her clinical practice and explains why. Her top tier includes BPC-157 for gut and musculoskeletal healing, TB-500 for systemic tissue repair and inflammation, GHK-Cu for skin and collagen support, and CJC-1295/Ipamorelin for growth hormone optimization.
What makes her commentary useful is the clinical context. She does not just describe what each peptide does in theory. She describes the patient profiles where she has seen the best results. BPC-157 works best for patients with chronic gut issues that have not responded to conventional treatment, and for athletes with stubborn soft tissue injuries. TB-500 shines in patients with widespread inflammation or autoimmune-driven tissue damage. GHK-Cu is her go-to for patients focused on skin quality and wound healing. The growth hormone secretagogues are reserved for patients with documented deficiencies or specific clinical goals that justify the IGF-1 elevation.
She also talks about what she does not prescribe and why. She avoids high-dose growth hormone peptides in patients with any cancer history. She is cautious with melanocyte-stimulating peptides like PT-141 and melanotan due to limited long-term safety data. And she has moved away from DSIP (Delta Sleep Inducing Peptide) because she found the clinical results inconsistent and the sourcing unreliable.
The Quality Control Problem
Dr. Froese dedicates a significant portion of the video to sourcing and quality, which is the single biggest practical concern for anyone using peptides. Unlike FDA-approved drugs, which are manufactured under strict Good Manufacturing Practice (GMP) standards, peptides from research chemical companies and overseas suppliers vary enormously in purity, potency, and sterility.
She has seen lab reports from patient-supplied peptides that showed 60-70% purity, meaning 30-40% of the product was unknown impurities. She has seen peptides contaminated with bacterial endotoxins. She has seen vials labeled as one peptide that contained a completely different compound. These are not hypothetical risks. They are things she has encountered in her own practice.
Her recommendation is to work exclusively with licensed compounding pharmacies that operate under USP 797 (sterile compounding) and USP 800 (hazardous drug handling) standards. These pharmacies test their products for identity, potency, sterility, and endotoxin content. The cost is higher than ordering from a research chemical website, but the difference in product quality is enormous.
How to Think About Risk When Human Data Is Limited
The most valuable part of this video is Dr. Froese framing how to evaluate risk in a space where randomized controlled trials are scarce. She uses a framework that considers three factors: the quality of the animal data, the plausibility of the mechanism, and the severity of what you are trying to treat.
For a peptide like BPC-157, the animal data is extensive and consistent across dozens of studies. The mechanism (nitric oxide modulation, growth factor upregulation) is well-characterized and biologically plausible. If the condition you are treating is a chronic injury that has failed conventional therapy, the risk-benefit calculation favors trying BPC-157 under medical supervision. The potential upside is high, the known risks are low, and the alternatives have already failed.
For a peptide with limited animal data, an unclear mechanism, and a cosmetic application, the calculation is very different. The potential upside is modest, the unknown risks could be significant, and there are usually lower-risk alternatives available.
This is just rational medicine, and it applies to conventional drugs as well. The difference with peptides is that the data gaps are larger, which means the uncertainty band around your risk estimate is wider. That is not a reason to avoid peptides. It is a reason to be more careful about which ones you use, what you use them for, and who supervises your care.
What Comes Next
If peptides interest you, the first step is finding a physician who has actual clinical experience with them. Not someone who read about peptides on a website and added them to their menu of services. Someone who has prescribed them to hundreds of patients, tracked outcomes, and adjusted their protocols based on what they observed. Dr. Froese is one such physician, but she is not the only one.
Start with a clear clinical question. What specific problem are you trying to solve? What conventional treatments have you already tried? What are the realistic expected outcomes from a peptide intervention? These questions should guide your decision, not enthusiasm or curiosity alone.
And prioritize sourcing above everything. A perfectly chosen peptide from a contaminated source is worse than no peptide at all. Compounding pharmacy, USP standards, third-party testing. Do not compromise on this.
One point Dr. Froese makes that resonates with anyone who has navigated the healthcare system: the current medical establishment is not set up to have nuanced conversations about peptides. Primary care physicians often have no training in this area and default to either dismissing peptides entirely or referring patients to specialists who may not exist in their area. Functional medicine practitioners may be enthusiastic about peptides but sometimes lack the clinical rigor that comes from formal pharmacology training. The ideal peptide provider sits at the intersection of conventional medical training and specific peptide knowledge, and those providers are still relatively rare.
Dr. Froese also addresses the cost of peptide therapy head-on. A typical monthly peptide protocol from a compounding pharmacy runs $150-$400 depending on the specific peptides and doses. Insurance does not cover any of it. For patients who are spending thousands of dollars on conventional treatments that are not working, the cost may be justified. For those who are using peptides for optimization rather than treating a specific condition, the cost-benefit calculation is different and should be made with clear eyes about what the evidence does and does not support for their particular goal.